Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

JW Therapeutics Starts China Trial of T-cell Immunotherapy for Liver Cancer

publication date: Mar 3, 2023

Shanghai’s JW Therapeutics started China trials of an autologous T-cell immunotherapy candidate that targets GPC-3 in patients with advanced hepatocellular carcinoma. JWATM214 combines the high affinity and specificity of the GPC-3 mAb with added cJun protein regulation to delay T cell exhaustion. JW expects the candidate, which incorporates Eureka's ARTEMIS® platform for better CAR-T drugs and Lyell's T cell anti-exhaustion technology for a more durable response with better anti-tumor activity than the competition. JW was originally formed as a JV between Seattle's Juno Therapeutics, a cell therapy biotech, and WuXi AppTec, a China CRDMO. More details....

Stock Symbol: (HK: 2126)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital